Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine - PubMed
6 hours ago
- #chemoresistance
- #glioblastoma
- #precision medicine
- Glioblastoma (GBM) is a highly lethal primary malignant brain tumor with median survival rarely exceeding 15 months despite aggressive treatment.
- Therapeutic resistance in GBM is driven by tumor cell adaptations, heterogeneity, and microenvironmental factors like the blood-brain barrier and hypoxia.
- Key resistance mechanisms include enhanced DNA repair, disrupted apoptosis, altered drug metabolism, and glioblastoma stem cell plasticity.
- Current strategies target DNA repair, oxidative stress, autophagy, and metabolic vulnerabilities but face limitations due to tumor heterogeneity.
- Precision oncology is hindered by a lack of validated predictive biomarkers, leaving many patients without actionable targets.
- Ex vivo functional drug sensitivity testing offers a complementary strategy by assessing individual tumor responses and guiding combination therapies.
- The review emphasizes the need to address GBM's heterogeneity and adaptive plasticity to improve treatment outcomes.